MTOR and neoplasm: Although ROS also support T-cell signaling following antigen recognition [223], a pharmacological boost of mitochondrial metabolic activity related to ROS upregulation has been reported to activate tumor-responsive T cells, amplifying the effectiveness of PD-1 blockade through the activation of AMPK, mTOR, and PGC-1α [224].